Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

retained text

Aurobindo Pharma share price climbed 1% in the morning trade on the BSE on Monday, 24 August, even as the pharma company said the US FDA conducted a routine inspection of its wholly owned step-down subsidiary in the US from 17th to 21st August 2026, which concluded with four observations.Aurobindo Pharma shares opened at ₹1,619.75 against their previous close of ₹1,619.95 and rose over 1% to an intraday high of ₹1,637.75.US subsidiary faces USFDA observationsIn an exchange filing on 24 August, Aurobindo Pharma said the United States Food and Drug Administration (US FDA) conducted a routine inspection at its wholly owned step-down subsidiary, Lannett Company LLC, located at Seymour, IN, USA, from 17th to 21st August 2026, which concluded with four observations.The company said the observations were procedural in nature, and it will respond to the US FDA within the stipulated timeline.(This is a developing story. Please check back for fresh updates.)

document fetched 2026-08-24 06:56 · canonical https://livemint.com/market/stock-market-news/aurobindo-pharma-us-subsidiary-lannett-company-llc-faces-4-observations-from-the-usfda-11787552311921.html